Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TYK2 | P29597 | 5/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | FGR | P09769 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | TEK | Q02763 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13929031 | 1.00 | CNR2 (0.39) | CNR2CNR1MEN1KMT2ATYK2 | |
| SCHEMBL13929029 | 0.90 | PDE4B (0.38) | CNR2CNR1MEN1KMT2ATYK2 | |
| SCHEMBL4191375 | 0.90 | PDE4B (0.38) | CNR2CNR1MEN1KMT2ATYK2 | |
| SCHEMBL5551331 | 0.90 | CNR2 (0.39) | CNR2CNR1TYK2 | |
| SCHEMBL4200607 | 0.83 | L3MBTL1 (0.53) | CNR2CNR1MEN1KMT2A | |
| SCHEMBL13929028 | 0.83 | L3MBTL1 (0.53) | CNR2CNR1MEN1KMT2A | |
| SCHEMBL5551244 | 0.80 | PDE4B (0.41) | CNR2CNR1TYK2PDE4BPDE4D | |
| SCHEMBL8299116 | 0.75 | CNR2 (0.48) | CNR2CNR1TYK2RAB9A | |
| SCHEMBL6012264 | 0.75 | CNR2 (0.60) | CNR2CNR1MEN1KMT2ATYK2 | |
| Hydrochloric Acid SCHEMBL4185132 | 0.74 | CNR2 (0.47) | CNR2CNR1TYK2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | claimed |
| US-20050020611-A1 | Compounds | PFIZER INC. | 2005-01-27 | — | — | US | claimed |
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1651640-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | BARBER CHRISTOPHER G | 2006-08-10 | — | — | US | disclosed |
| US-20050043326-A1 | Compounds | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| US-20050020611-A1 | Compounds | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020611-A1 | Compounds | NQO1, NAMPT, NNT | CNR2 571/4885CNR1 529/4885MEN1 532/4885 |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | PDE4A, PDE4B, PDE4C | CNR2 1750/4885CNR1 1800/4885MEN1 1891/4885 |
| US-20090035313-A1 | Compounds | NQO1, NAMPT, NNT | CNR2 571/4885CNR1 529/4885MEN1 532/4885 |
| US-20050043326-A1 | Compounds | NQO1, NAMPT, NNT | CNR2 571/4885CNR1 529/4885MEN1 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.